Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Dunsford
Jennifer
J
CancerCare Manitoba, Winnipeg, MB, Canada. jennifer.dunsford@cancercare.mb.ca
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D003967:Diarrhea / Q000139:chemically induced / Q000451:nursing* / Q000517:prevention & control; D003875:Drug Eruptions / Q000209:etiology / Q000451:nursing* / Q000517:prevention & control; D016903:Drug Monitoring; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D009730:Nursing Assessment; D009859:Oncology Nursing / Q000458:organization & administration; D000077544:Panitumumab; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077544:Panitumumab; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000068818:Cetuximab; D000077156:Gefitinib